Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
HaoBo Medicine is a clinical-stage biotechnology company focused on the discovery and development of innovative siRNA (small interfering RNA) therapeutics. The company leverages its proprietary Med-S-Gal platform, a GalNAc-based delivery technology, to target liver-expressed genes involved in chronic diseases. Its lead program, HB001, is currently in Phase 1 clinical trials for the treatment of chronic Hepatitis B, aiming for a functional cure. Beyond infectious diseases, HaoBo is advancing a pipeline of candidates for metabolic and cardiovascular indications, including NASH and hyperlipidemia. With operations in Shanghai and the San Francisco Bay Area, the company integrates global R&D capabilities to accelerate the delivery of nucleic acid medicines.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on HaoBo Medicine.